NCT03905148
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03905148
Title Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors BeiGene
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | AUS

Facility Status City State Zip Country Details
University of California Los Angeles Santa Monica California 90404 United States Details
MD Anderson Houston Texas 77030 United States Details
Blacktown Cancer and Haematology Centre Blacktown New South Wales 2148 Australia Details
The Prince of Wales Private Hospital - Specialist Medical Randwick Randwick New South Wales 2031 Australia Details
Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia Details
Linear Clinical Research Nedlands Western Australia 6009 Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field